share_log

GlaxoSmithKline | 6-K: Viiv Healthcare Announces Interim Data at Croi Indicating Superior Efficacy of Long-Acting Injectable Hiv Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living with Hiv Who Have Adheren

SEC announcement ·  Mar 6 11:13
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more